Recommended

Discover how to overcome low affinity or poor TCR yields that are slowing you down in this upcoming webinar – register your details today
Facing roadblocks in obesity drug discovery? Discover how integrated, validated strategies are helping teams accelerate development and reduce risk – register your details now
Unlock the science, strategy and real-world impact behind the next generation of precision therapies – access our new brand report now >>
Safety data is no longer just a regulatory checkbox – it’s a strategic advantage. Find out more in our upcoming webinar, register your details today
Explore how AI is reshaping early drug discovery, from target identification and compound screening to predictive modelling and trial design – register now!
news

Award recognises innovative label-free technology

A Frost & Sullivan award has been given to a new label-free single-cell analysis and sorting platform for utilising cutting-edge technologies.

Stem cell discovery

An award from Frost & Sullivan has recognised a new automated, high-content, label-free single-cell analysis and sorting platform. According to the organisation, the accolade is presented for an innovative element in a product which leverages pioneering technologies.

The 2019 Global New Product Innovation Award was granted to LumaCyte for its Laser Force Cytology™ (LFC™) technology, a part of the Radiance® platform. This is due to its capability to accelerate therapies and analytical insights by enabling new cell discovery, characterisation and phenotyping across a broad range of applications.

The platform can be used for viral quantification, required for assays in vaccine and cell and gene therapy development and production. The technology evaluates single suspended or fixed cells directly without the use of antibody or genetic labelling, which eliminates research bias when investigating changes in cell populations.

 

Reserve your FREE place

 


Reduce preclinical failures with smarter off-target profiling

24 September 2025 | 15:00PM BST | FREE Webinar

Join this webinar to hear from Dr Emilie Desfosses as she shares insights into how in vitro and in silico methods can support more informed, human-relevant safety decisions -especially as ethical and regulatory changes continue to reshape preclinical research.

What you’ll learn:

  • Approaches for prioritizing follow-up studies and refining risk mitigation strategies
  • How to interpret hit profiles from binding and functional assays
  • Strategies for identifying organ systems at risk based on target activity modulation
  • How to use visualization tools to assess safety margins and compare compound profiles

Register Now – It’s Free!

 

“[This] novel approach empowers the discovery, characterisation and sorting of cells from biological samples based upon their inherent physical, biochemical and biological characteristics. As a result, LumaCyte can offer direct-from-cell sample to analysis/sorting with no antibody staining, processing, antibody-induced phenotype changes or fixation,” said Christi Bird Ulan, Principal Consultant at Frost & Sullivan.

By measuring subtle changes in unique biochemical and biophysical cellular properties, the platform can yield new data and insights to understand cellular systems using optical force, microfluidics, imaging and robust multivariate data. Its label-free applications include gene expression, cell clearance and epigenetics, as well as quality control and process optimisation for biomanufacturing.